CN1080189A - Small-dose inactivated vaccine - Google Patents
Small-dose inactivated vaccine Download PDFInfo
- Publication number
- CN1080189A CN1080189A CN 93103140 CN93103140A CN1080189A CN 1080189 A CN1080189 A CN 1080189A CN 93103140 CN93103140 CN 93103140 CN 93103140 A CN93103140 A CN 93103140A CN 1080189 A CN1080189 A CN 1080189A
- Authority
- CN
- China
- Prior art keywords
- present
- guerin
- vaccine
- treatment
- deactivation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to do the improvement medicament of raw material with bacillus calmette-guerin vaccine.The water preparation that small-dose inactivated vaccine of the present invention is obtained after deactivation with bacillus calmette-guerin vaccine by inoculation, every milliliter contains deactivation bacill calmette-guerin amount is 0.75～2 milligram.The present invention reaches the purpose of regulation and control body's immunity with minimum dose, has no side effect, and can carry out the treatment of long period to the disease that asthma etc. is difficult to effect a radical cure, and reaches the purpose of consolidating curative effect.Treatment infantile asthma, bronchitis, the recent effective percentage of repetitive upper respiratory tract infection is respectively 92.0%, 96.0%, 98.0%, infantile asthma long-term effective rate 91%.The present invention is inexpensive, and is easy to use, can extensively promote in town and country, has practical value.
Description
The present invention relates to a kind of medical drugs, particularly about make the improvement medicament of raw material with bacillus calmette-guerin vaccine.
Bacillus calmette-guerin vaccine is a bacillus tuberculosis bovis, is commissioned to train through more than 100 and supports the live vaccine that toxicity lowers, and is used for the tuberculosis prophylaxis inoculation, and effect duration is very short, and water preparation dosage form 1 month is promptly expired.General at present use freeze dried powder is extended the expiration date.Clinical usefulness bacillus calmette-guerin vaccine is before the deadline made intradermal injection, and the bacill calmette-guerin amount is 0.75 mg/ml, uses as improving antiphthisic immunity.Discover that bacillus calmette-guerin vaccine has the immunological adjuvant activity, the bacillus calmette-guerin vaccine of human deactivation is arranged, the bacill calmette-guerin amount is 75 mg/ml, and cut dispenser on the percutaneous improves immune function of human body.After patient's medication local can produce red and swollen, fester, reaction such as microabscess.Patient can not adhere to medication, should not the longer course of treatment, do not reach therapeutic effect.
The present invention to provide a kind of novel be the medicament of raw material with the bacillus calmette-guerin vaccine, this medicament utilizes expired or is about to out of date bacillus calmette-guerin vaccine makes raw material, has reliable mediator's body immunity function, there is not the effect of paying, energy long period medication improves curative effect, the acceptable characteristics of patient.
The present invention is a kind of small-dose inactivated vaccine, and by the water preparation that inoculation obtains after deactivation with bacillus calmette-guerin vaccine, every milliliter contains deactivation bacill calmette-guerin amount is 0.75～2 milligram.
What the present invention was different with existing medicament is to have adopted small-dose inactivated vaccine, also uses low dose now, but without deactivation, is specificity, and as the tuberculosis prophylaxis inoculation, this medicament is used for intradermal injection.The bacillus calmette-guerin vaccine of deactivation also has the human mistake, but dosage is big, is 37.5 times to 100 times of the present invention, and the effect of paying is big, is used for scarification.
The present invention is on probation through animal and human body, finds a kind of minimum dose to reach the medicament of therapeutic effect.It mainly acts on is to stimulate monokaryon one macrophage and T cell, and the B cell is had potentiation, also can strengthen the function of NK cell.The present invention adopts the technical characterictic of inactivated vaccine, and the utilization rate of bacillus calmette-guerin vaccine is greatly improved, and provides new purposes for being considered as out of date medicine originally.The present invention adopts low dose of technical characterictic.Both guaranteed curative effect, can reduce the effect of paying again, or do not had the effect of paying, can extend the period of treatment, can carry out the treatment of long period, reached the purpose of consolidating curative effect the disease of refractory such as asthma.In addition, the present invention makes easy to use, and is inexpensive, can extensively promote in town and country, has practical value.
Below the invention will be further described with embodiment.
The embodiment raw material: the lyophilized bacillus calmette-guerin vaccine powder that the Shanghai biological study is produced, out of date or be about to out of dately all can.
The embodiment manufacture method: under aseptic condition, the lyophilized bacillus calmette-guerin vaccine powder is even with physiological saline solution, and every milliliter contains 0.75 milligram in the packing ampoule, or 0.85 milligram, or 0.95 milligram or 1.10 milligrams, or 1.20 milligrams, or 1.30 milligrams, or 1.40 milligrams, or 1.50 milligrams, or 1.60 milligrams, or 1.70 milligrams, or 1.80 milligrams, or 1.90 milligrams, or 2.0 milligrams tulase.Install the envelope small jar, place 60 ℃ of water bath deactivations, take out after 60 minutes, place in the cryogenic refrigerator and preserve, standby.
Product standard: the water preparation after the deactivation is done tulase and is cultivated, no tulase growth.
The embodiment using method: get 0.1 milliliter of finished product, 2/3 district under the facies medialis brachii before dropping in, three of children's's scarifications are grown up four, and every is about 1 centimetre, and cut is not hemorrhage to be degree, natural drying, red line appears in the part.Treat once weekly, 10 times is a course of treatment, generally carries out 1～2 course of treatment.But strengthen treatment in order to consolidate the curative effect proper extension course of treatment or good morbidity season.
Rabbit test method and result: make 20 Japan large ear rabbits of immunologic hypofunction with cyclophosphamide, and be divided into two groups with random table, one group gives embodiment finished product injection for curing, and another group is given any treatment.Treatment group lymhocyte transformation rate improves, and the reaction of PHA skin test blush increases, and lymphocyte absolute value increases.Two groups relatively, difference highly significant (the P value is all less than 0.01).
Scarification of the present invention is used in infantile asthma 252 examples, bronchitis 52 examples, and repetitive upper respiratory tract infection 70 examples have effectively been regulated body's immunity, and patient symptom alleviates, and frequency of disease development reduces or recovery from illness.Effective percentage is respectively 92.0%, 96.0%, 98.0% in the recent period, does not see any pair of reaction.Before and after the treatment, measure through multiple immune indexes, the result is that treatment back IgG, IgA are significantly improved, and PHA skin test reaction blush enlarges RBCC
3The b receptor active increases, and prompting treatment back cellular immunization and humoral immune function all have enhancing.Infantile asthma 151 examples were observed 5 years, and late result cures 61%, takes a turn for the better 30%, total effective rate 91%.
The present invention also can be used for treating the asthma bronchitis of growing up, senile chronic bronchitis, hepatitis B, allergic rhinitis, urticaria, immunologic function disequilibriums such as malignant tumor postoperative and the immune disease relevant with immunity.
Claims (1)
1, small-dose inactivated vaccine, by the water preparation that inoculation obtains after deactivation with bacillus calmette-guerin vaccine, every milliliter contains deactivation bacill calmette-guerin amount is 0.75～2 milligram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103140A CN1038390C (en) | 1993-03-20 | 1993-03-20 | Small-dose inactivated vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93103140A CN1038390C (en) | 1993-03-20 | 1993-03-20 | Small-dose inactivated vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1080189A true CN1080189A (en) | 1994-01-05 |
| CN1038390C CN1038390C (en) | 1998-05-20 |
Family
ID=4984485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93103140A Expired - Fee Related CN1038390C (en) | 1993-03-20 | 1993-03-20 | Small-dose inactivated vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1038390C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104582721A (en) * | 2012-06-15 | 2015-04-29 | “德国三叠纪爱普霍尔”医学研究基础学院(Igtp) | Inactivated mycobacteria for oral use in the prevention of tuberculosis |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069743B (en) * | 2004-07-27 | 2011-04-06 | 张锦铭 | Use of inactive BCG vaccine in preparation of use for treatment of allergic action diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152423A (en) * | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
| GB9024320D0 (en) * | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
-
1993
- 1993-03-20 CN CN93103140A patent/CN1038390C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104582721A (en) * | 2012-06-15 | 2015-04-29 | “德国三叠纪爱普霍尔”医学研究基础学院(Igtp) | Inactivated mycobacteria for oral use in the prevention of tuberculosis |
| CN104582721B (en) * | 2012-06-15 | 2018-01-26 | “德国三叠纪爱普霍尔”医学研究基础学院(Igtp) | For preventing oral killed mycobacteria lungy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1038390C (en) | 1998-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101933959B (en) | Medicament for treating canker and preparation method thereof | |
| CN103705616A (en) | Formula of paste for removing slough and promoting growth of tissue regeneration | |
| CN1159918A (en) | Method for preparing anticancer bioactive peptide preparation | |
| CN106362125A (en) | Health-care foot patch and application method thereof | |
| CN1038390C (en) | Small-dose inactivated vaccine | |
| CN103566026A (en) | Burn medicament, and preparation method and application thereof | |
| CN102727581A (en) | Pharmaceutical composition with wound repairing effect | |
| WO2001054727A1 (en) | Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes | |
| CN101069743B (en) | Use of inactive BCG vaccine in preparation of use for treatment of allergic action diseases | |
| CN102178915A (en) | Hair growing fluid | |
| CN101676401B (en) | Scorpion extract | |
| CN101653474B (en) | Medicine for treating hemorrhoid and its preparing process | |
| CN105168358A (en) | Traditional Chinese medicine composition for treating bone fractures | |
| CN110384748A (en) | A kind of weapons wound badu shengji powder | |
| CN1602956A (en) | Deactivated BCG for treating disease | |
| CN103202641A (en) | Cervical adjustment treating medicine pillow | |
| CN103550618A (en) | Medicine for preventing and treating infectious cold | |
| CN106955306A (en) | A kind of traditional Chinese medicine for treating cub diarrhoea and preparation method thereof | |
| CN108543010A (en) | A kind of preparation method and applications for treating pig asthma syndrome bacterium solution | |
| CN1098293A (en) | Scorpion venom injection and method for making thereof and usage | |
| CN100551384C (en) | A kind of plaster for the treatment of hyperosteogeny, neuropathic pain and multiple inflammation | |
| CN1250661A (en) | Medicinal composition for treating bone fracture and its preparing process | |
| CN1401350A (en) | Medicine for treating burns and scald, and producing method thereof | |
| CN2398992Y (en) | Medicinal bag type cervical vertebra traction bandage | |
| JPS59110626A (en) | Pertussis vaccine containing b-oligomer and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 19980520 Termination date: 20110320 |